Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2024 Jun;99(6):971-979. doi: 10.1016/j.mayocp.2024.02.022.
Clostridioides difficile infection (CDI) is a significant public health challenge in the developed world. Although previously CDI was primarily a health care-acquired infection, there are now rising numbers of community-acquired cases in patients without traditional risk factors, such as antibiotic exposure. The landscape for the treatment of CDI has changed significantly during the past decade, including newer diagnostic tests, novel antibiotic regimens, and strategies for microbiome restoration in the form of traditional fecal microbiota transplant and approved live biotherapeutics in an effort to address the underlying pathophysiologic process of gut microbial dysbiosis. We present a concise review for clinicians on the diagnosis and management of both primary and recurrent CDI.
艰难梭菌感染(CDI)是发达国家面临的重大公共卫生挑战。尽管以前 CDI 主要是医源性感染,但现在在没有传统危险因素(如抗生素暴露)的患者中,社区获得性病例的数量正在上升。在过去十年中,CDI 的治疗方法发生了重大变化,包括新的诊断测试、新型抗生素方案以及以传统粪便微生物移植和批准的活体生物治疗为形式的微生物组恢复策略,以解决肠道微生物失调的潜在病理生理过程。我们为临床医生提供了关于原发性和复发性 CDI 的诊断和管理的简明综述。
Mayo Clin Proc. 2024-6
Gut Microbes. 2022
Expert Rev Gastroenterol Hepatol. 2023
Clin Infect Dis. 2023-12-5
J Manag Care Spec Pharm. 2020-12
Front Endocrinol (Lausanne). 2025-6-6
J Clin Med. 2024-6-26